Sionna Therapeutics, Inc. (SION)
SION moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How SION actually reacts to news — the realized, point-in-time move the market made, measured across 321 labeled events over the last three years with zero look-ahead.
SION’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 312 |
| 30-min | 0.00% | 48% | 312 |
| 60-min | -0.26% | 46% | 312 |
| to close | 0.00% | 48% | 311 |
| Middle 50% of SION reactions | -2.24% to +1.70% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 321 |
Half of all Sionna Therapeutics, Inc. news events land between -2.24% and +1.70% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SION reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 26 | +0.12% | 50% | +4.30% |
| Coverage initiations | 30 | +0.70% | 77% | -1.35% |
| Rating reiterations | 30 | -0.18% | 47% | +0.56% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how SION ranks against every other measured name →
That’s how SION usually reacts — get an email when it moves on news →Email me when SION moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SION's baseline. Nothing else.
Recent SION events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference | Press release | GlobeNewswire | -0.20% | -0.61% | |
| Form 8-K Sionna Therapeutics, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | -8.62% | |
| Form 8-K Sionna Therapeutics, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -3.30% | -12.58% | |
| Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial | Press release | GlobeNewswire | -3.30% | -12.58% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bronstein, Gewirtz & Grossman, LLC (SION) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.71% | -3.43% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sionna Therapeutics, Inc. (SION) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.74% | +11.24% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Sionna Therapeutics, Inc. (SION) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.04% | +5.17% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sionna Therapeutics, Inc. (SION) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.17% | +2.03% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sionna Therapeutics, Inc. (SION) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -1.36% | +2.73% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sionna Therapeutics, Inc. (SION) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.58% | -2.41% | |
| Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.16% | +0.65% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sionna Therapeutics, Inc. (SION) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.37% | +3.33% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sionna Therapeutics, Inc. (SION) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.38% | +5.47% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Sionna Therapeutics, Inc. (SION) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.09% | -3.02% | |
| Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.26% | -4.33% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sionna Therapeutics, Inc. (SION) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.74% | +3.31% | |
| SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +1.08% | -8.65% | |
| Form 8-K Sionna Therapeutics, For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | -10.49% | — | |
| Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | Press release | GlobeNewswire | — | — | |
| Form 10-Q Sionna Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.20% | +5.31% | |
| Form 8-K Sionna Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.20% | +5.31% | |
| Sionna Therapeutics Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.20% | +5.31% | |
| Form 8-K Sionna Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +2.88% | +2.48% | |
| Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences | Press release | GlobeNewswire | -0.24% | -0.07% | |
| Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference | Press release | GlobeNewswire | -0.76% | +5.74% | |
| Form 10-Q Sionna Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.04% | -9.16% | |
| Form 8-K Sionna Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -5.04% | -9.16% | |
| Sionna Therapeutics Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -5.04% | -9.16% | |
| Form ARS Sionna Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.24% | -0.23% | |
| Form DEF 14A Sionna Therapeutics, For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | -1.24% | -0.23% | |
| Form DEFA14A Sionna Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.24% | -0.23% | |
| Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | Press release | GlobeNewswire | +6.13% | +3.13% | |
| Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium | Press release | GlobeNewswire | -0.89% | -0.94% | |
| Form 10-K Sionna Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.25% | +3.13% | |
| Form 8-K Sionna Therapeutics, For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +5.25% | +3.13% | |
| Form S-3ASR Sionna Therapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | +5.25% | +3.13% | |
| Form S-8 Sionna Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +5.25% | +3.13% | |
| Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +5.25% | +3.13% | |
| Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences | Press release | GlobeNewswire | +2.49% | +3.17% | |
| Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | -1.27% | -7.16% | |
| Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.47% | +4.74% | |
| Sionna Therapeutics to Participate in Upcoming December Investor Conferences | Press release | GlobeNewswire | +0.14% | +0.86% | |
| The NEVYs 2025 Nominees Revealed: New England's Innovation Leaders Take Center Stage | Press release | PR Web | +1.01% | +3.82% | |
| Form 10-Q Sionna Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.32% | |
| Form 8-K Sionna Therapeutics, For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.32% | |
| Sionna Therapeutics Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.00% | -1.32% | |
| Sionna Therapeutics to Participate in Upcoming November Investor Conferences | Press release | GlobeNewswire | +0.81% | +0.82% | |
| Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference | Press release | GlobeNewswire | +0.78% | -1.11% | |
| Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis | Press release | GlobeNewswire | +1.10% | +32.03% | |
| Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference | Press release | GlobeNewswire | +2.14% | +6.12% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SION section they belong to.
Where else SION is measured.
SION earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sionna Therapeutics, Inc.'s median reaction calculated?
Every labeled SION news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 321 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of SION's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SION's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.